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Background: Patients with COPD have frequent exacerbations. The role of respiratory viral
infection is just emerging. We wished to determine prospectively the incidence of viral
infection in exacerbated and stable COPD patients as well as smokers who do not have airways
obstruction.
Methods: Stable and exacerbated COPD patients were recruited along with a group of patients
who had smoked but who did not have any airways obstruction. Spirometry was performed and
sputum specimens were tested for a range of 12 different respiratory viruses using PCR.
Results: One hundred and thirty-six patients with exacerbations of COPD, 68 stable COPD
patients and 16 non-obstructed smokers were recruited. A respiratory virus was detected in
37% of exacerbations, 12% of stable COPD patients and 12% of non-obstructed smokers,
p < 0.0005. Rhinovirus was most frequently detected. The symptom of fever was associated
with virus detection, p < 0.05. Infection with more than one virus was only found in the
exacerbated COPD patients.
Conclusion: Respiratory viral infection is associated with exacerbations of COPD. Rhinovirus
was the most common infecting agent identified and in two cases human metapneumovirus
was also detected. Dual infections were only seen amongst those patients admitted to hospital
with acute exacerbations of COPD. Viruses were more commonly detected in those with more
severe airways disease.
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Patients with COPD have frequent exacerbations which lead
to increased airway inflammation and often subsequent
hospitalization.1 Bacteria are associatedwith approximately.
1576 T.E. McManus et al.50% of exacerbations.2,3 A number of studies have identified
viral infections of the respiratory tract as precipitating
agents. Studies using serology and viral culture identified re-
spiratory viruses in 30% of patients during acute exacerba-
tions of COPD.4 With the development of more sensitive
molecular tests the role of viruses in COPD has been better
defined. Walsh et al. identified several common respiratory
viruses in a cohort of patients with COPD or congestive
cardiac failure.5 Viruses were identified by serology and viral
culture methods. Significant outcomes in terms of hospital-
isation were seen for respiratory syncytial virus (RSV) and
influenza A infected patients. Greenberg et al., using serol-
ogy and viral culture, showed that in 23% of cases of hospital-
isation of COPD patients a virus was detected and that the
mean time to return to symptomatic baseline was 2 weeks.6
Themost common viruses identifiedwere of the picornavirus
classification (rhinoviruses).
Several studies have used PCR for the diagnosis of viral
infection. Initially, in 2000 Seemungal et al. examined 33
patients with COPD when stable and subsequently during an
exacerbation.7 Ten of 43 exacerbations were associated
with rhinovirus infection. Higher symptom scores and
sputum interleukin-6 levels were seen with rhinovirus
exacerbations. Seemungal et al. went on to show respira-
tory viral infection in 39% of exacerbations of COPD.8 Viral
infection was associated with a more severe exacerbation,
and in patients who had a higher frequency of exacerba-
tions, i.e. those with the poorest lung function. Patients
were reviewed in convalescence at 4e6 weeks. The major-
ity (58%) of these viruses were rhinovirus (i.e. 23% of COPD
exacerbations). Plasma IL-6 levels were elevated in all
exacerbations, and levels were significantly increased in
the virus positive group when comparison was made with
those in whom no virus was detected.
Rohde et al. used PCR to detect viruses in patients with
exacerbations of COPD. A respiratory virus was detected in
56% of cases in comparison to 19% of control subjects with
stable COPD.9 The majority of viruses detected were
picornaviruses. The most recent study from Beckham
et al. combined specimens obtained for two previous
studies for analysis by PCR.10 They detected a respiratory
viral infection in 42% of acute respiratory illnesses. Respira-
tory viral infection in COPD patients during exacerbation
has been associated with longer median symptom recovery
time in comparison to exacerbations in which a viral agent
was not identified (13 days versus 6 days respectively).8
The hypothesis tested in the present study was that
acute respiratory viral infection is implicated in the
pathogenesis of COPD exacerbations. The aims of the
present study were to examine respiratory specimens for
the presence of respiratory viruses in patients with COPD
whilst stable and also during exacerbations.
Methods
Subjects
This study was approved by the Queen’s University Belfast
ethics committee and all patients gave written consent. The
patient groups described in this paper have been described
in other related publications. Patients hospitalised withexacerbations of COPD were recruited within 24 h of presen-
tation over a 2-year period. A further group of stable COPD
patients were also recruited. Stability was defined as no
change in respiratory symptoms or alteration in therapy in
the previous 8 weeks. Patient’s symptoms were recorded in
a binary format. Spirometry was performed, the best of 3
reproducible readings was taken (Vitalograph spirometer,
Vitalograph, Buckingham, UK).11 Spirometry was repeated
after nebulised beta agonist (salbutamol 2.5 mg). Any
patients with significant improvement in FEV1 (>200 ml/
15%) were excluded. Those patients with a history of bron-
chiectasis, neoplastic process or other serious concomitant
disease were excluded.
Definitions
COPD and assessment of severity was classified according to
the GOLD criteria.12 Exacerbation of COPD was classified
according to the GOLD criteria with symptoms of increased
dyspnoea, increased cough or increased sputum produc-
tion.13 Stable COPD was classified according to the GOLD
criteria without any symptoms of exacerbation or changes
in treatment within the last 8 weeks.
Samples
Sputum samples were obtained either by spontaneous
production or following nebulised hypertonic saline.
Briefly, 4 ml of 3% saline was nebulised via an air driven
nebuliser. Every 5 min spirometry was repeated to mea-
sure FEV1, and nebulisation continued if FEV1 had not
fallen by more than 20%. This was continued up to
20 min. All sputum expectorated was collected. All sam-
ples were processed within 2 h. Specimens were mixed
with 4 volumes of 0.1% dithiothreitol (Sigma, Poole, UK)
and shaken in an orbital incubator (Gallenkamp, Lough-
borough, UK) for 15 min at 37 C followed by the addition
of 4 volumes of phosphate buffered saline and shaken for
a further 5 min. The resulting suspension was then filtered
through 50 mm Nylon Gauze (Lockertex, Warrington, UK)
and spun down at 1000  g for 10 min. After removing
the supernatant the cell pellet was resuspended in Lysis
Buffer (Qiagen, Crawley, UK). Total nucleic acid extrac-
tion was performed on 200 ml of sputum sample suspended
in Lysis Buffer (QIAamp DNA Blood Mini Kit).
Polymerase chain reaction
Extracted samples were screened for common respiratory
viruses (rhinovirus, human metapneumovirus, influenza A
H1 and H3, influenza B, RSV A and B, coronavirus 229E,
adenovirus and parainfluenza 1, 2 and 3) using an eight-well
multiplexed, nested PCR system (Fig. 1).14 A positive
control was used for each set of patient’s tests. Mastermix
and PCR cycling conditions are listed in the Supplementary
material(appendix A1 and A2 respectively). Tests results
were accepted as being valid when the positive control
tested positive with correct sized product(s). A positive
result was noted when second (or first and second) round
products were noted and confirmed as being the correct
size. Indeterminate test results were repeated. This
Figure 1 Nested PCR for respiratory virus screen with 1st and
2nd round products. Specimen positive for influenza A H3 (lane 4),
with positive control of parainfluenza 1 (lane 8). Molecular
weight markers flank specimens.
Table 1 Patient demographics and results of
investigations
Measurement Patient group
Exacerbated
COPD
Stable COPD Non-
obstructed
smokers
No. patients 136 68 16
Sex (M/F) 64/72 30/38 4/12
Age 70.2  9.4 66.3  9.4 52.2  7.6
FEV1, litres
(% Pred)
0.84  0.47
(39  20)
1.00  0.53
(48  22)
2.60  0.56
(105  11)
Tobacco
(packs/year)
48.0  39.2a 42.2  26.0b 44.0  21.5
C reactive
protein
14.8
(5.0e70.2)c
5.0 (5.0e8.4) 5.0
(5.0e5.0)
White cell
count
10.9  3.7c 8.7  2.6 8.6  2.7
Neutrophil
count
7.9  3.6c 5.4  2.3 4.9  2.2
BMI 25.4  6.1 26.0  5.2 29.0  5.3
a Exacerbated versus stable; pZ 0.21, 95% CI 3.3e14.9.
b Stable COPD versus NOS; pZ 0.66, 95% CI 15.6e10.1.
c COPD exacerbation versus stable COPD; p < 0.0001.
Viral infection and COPD 1577method allowed rapid testing of clinical specimens for mul-
tiple viruses with sensitive and specific assays.
Statistical analysis
A power calculation was performed to determine study
group sizes. Assuming a respiratory virus detection rate of
30% amongst COPD patients during exacerbations and 10%
detection when stable a power calculation was performed
using EpiInfo version 6. Using a confidence value of 95%
with a power of 80% and a 2:1 ratio of group sizes, 111
patients with COPD exacerbations and 56 stable COPD
subjects were required.Normally distributed data were presented as mean  stan-
dard deviation, whilst non-parametric data were expressed
as median and inter quartile ranges. Normally distributed
continuous variables were compared by t-test; otherwise
the differences were assessed by the ManneWhitney U-
test. For discrete variables frequencies and percentages
were reported and groups compared using the chi squared
test. A significance level of 5% was chosen. Statistical anal-
ysis was carried out using SPSS (Chicago, IL) version 10.0.
Results
Subjects
A total of 220 subjects were recruited in this study (Table 1);
136 were seen during an acute exacerbation, and 68 were
recruited when stable. An additional 16 non-obstructed
smokers with a FEV1 and FVC within the normal range
were recruited. Patient characteristics are shown in Tables
1 and 2; the exacerbated and stable COPD groups were of
similar age, sex, FEV1, tobacco use, baseline MRC score, in-
haled steroid and body mass index (BMI) and pack years of
tobacco use.
Blood investigations
CRP and white cell count (WCC) were significantly elevated
during exacerbation when compared to stable COPD
patients. CRP levels were 14.8 mg/dl (5.0e70.2 mg/dl) at
exacerbation and 5.0 mg/dl (5.0e8.4 mg/dl) in stable
patients (p < 0.0001). The WCC increased from 8.7  2.6 to
10.9  3.7  103/l in exacerbations of COPD (p < 0.0001).
Similarly the neutrophil count increased from 5.4  2.3 to
Table 2 Patient medication
Measurement Patient group
Exacerbated
COPD
Stable
COPD
Non-
obstructed
smokers
No. patients 136 68 16
Short acting b2
agonist
80 40 0
Long acting b2
agonist
57 42 0
Inhaled steroid 94 53 0
Inhaled steroid
(BDP)
1040  727 949  588 e
Oral theophylline 45 23 0
Theophylline (mg) 482  189 524  198 e
Nebulised
therapy
86 28 0
Home oxygen 39 11 0
Maintenance
oral steroids
9 6 0
1578 T.E. McManus et al.7.9  3.6 during exacerbations (p < 0.0001). Duration of stay
in hospital correlated (Pearson’s) with the CRP level on
admission, rZ 0.22, p < 0.05.
Patients’ symptoms
The majority of patients described symptoms of increased
dyspnoea, cough along with increased sputum volume and
purulence during exacerbations (Table 3). The presence of
fever was associated with the identification in the same
patient, p < 0.05. The majority of patients were MRC score
5 during exacerbations.Table 3 Patient symptoms during exacerbations
Measurement Recorded during
an exacerbation
Total number of patients 136
Increased dyspnoea (%) 134 (99)
Increased sputum volume (%) 88 (65)
Increased sputum purulence (%) 81 (60)
Increased cough (%) 105 (77)
Nasal discharge/congestion (%) 75 (55)
Wheeze (%) 110 (81)
Sore throat (%) 34 (25)
Fever (%)a 38 (28)
Anthonisen scoreb 1.8  0.8
Total symptom score 4.6  1.5
MRC score 5.0 (5.0e5.0)
Symptom score is based on the sum value of binary coded respi-
ratory symptoms: dyspnoea, increased sputum purulence, in-
creased sputum volume, nasal discharge/congestion, wheeze,
sore throat and cough.
a Chi squared test, fever and respiratory virus detection,
p < 0.01.
b Anthonisen criteria.13Respiratory virus detection
Respiratory viruses were detected in sputum and nasal/
throat swabs in 50 of 136 (37%) patients during exacerba-
tions of COPD and 8 of 68 (12%) stable COPD patients
(p < 0.0001) (Table 4). The viruses detected (Table 5) were
rhinovirus (57%), adenovirus (18%), parainfluenza 3 (9%), In-
fluenza A H3 (5%), RSV B (3.5%), metapneumovirus (3.5%),
coronavirus (2%) and RSV A (2%). There were dual infections
in six cases however these were all confined to the exacer-
bated COPD group. A respiratory virus was more frequently
detected during exacerbations in patients with more severe
airways disease, p < 0.05 (Table 6). No associations were
seen between viral infection and patient sex or medication
(use of theophylline or inhaled steroid therapy).
Discussion
The main findings of this study were that respiratory viruses
were more frequently detected during acute exacerbations
of COPD in patients admitted to hospital and that CRP
levels correlated with exacerbation and duration of hospi-
tal stay. This study was performed over a 2-year period in
order to avoid bias due to seasonality.
The detection rate of respiratory viruses during exacer-
bations of COPD in this study (37%) is comparable to results
obtained by Seemungal et al. (39.2%)8 and Beckham et al.
41.8%)10 but less than the findings of Rohde et al. (56%).9
Lower detection rates may be related to time of sampling
as patients presenting to hospital had developed symptoms
for a median of 5 days prior to admission.
This is the first study to prospectively analyse this range
of respiratory viruses in patients recruited during exacer-
bation of COPD. The most common infecting agent was
rhinovirus in keeping with previous studies,8e10 however we
also detected a high rate of adenoviral infection which has
not previously been reported. This is in keeping with the
findings of Coyle et al. who demonstrated that adenovirus
is more commonly detected using PCR than conventional
immunofluorescence and virus culture techniques.14 Previ-
ous investigators have related adenoviral infection to
subsequent latent infection in the form of adenovirus E1A
and that it may be important in the pathogenesis of
COPD.15
Metapneumovirus was discovered in 2001 and initially
detected in young children with a respiratory tract illness.16
It was subsequently found to play a role in community-
acquired respiratory tract illness with 2.2% of patients
presenting with ’influenza-like illness’ testing positive.17Table 4 Respiratory viral infection group comparisons
Groups Odds ratio
(95% CI)
Relative risk
(95% CI)
p value
Exacerbated vs
stable
4.4 (1.8e10.8) 3.1 (1.6e6.2) 0.0002
Stable vs NOSa 0.9 (0.2e7.2) 0.9 (0.2e4.0) 0.93
a Non-obstructed smokers (NOS), patients who have smoked
but who have normal spirometry.
Table 5 Respiratory viral infection
Variable Patient group
Exacerbated
COPD
Stable
COPD
Non-
obstructed
smokers
No. patients 136 68 16
Respiratory viral
screen positive (%)
50 (36.8)a 8 (11.8) 2 (12.5)
Rhinovirus 32 3 0
Adenovirus 10 4 1
Influenza A H1 0 0 0
Influenza A H3 3 0 0
Influenza B 0 0 0
Metapneumovirus 2 0 0
Parainfluenza 1 0 0 0
Parainfluenza 2 0 0 0
Parainfluenza 3 5 0 1
Coronavirus 1 1 0
RSV A 1 0 0
RSV B 2 0 0
Dual infections
Flu A H3 and Adv 2 0 0
Rhinovirus and
adenovirus
2 0 0
Rhinovirus and
parainfluenza 3
2 0 0
a p < 0.0005 (respiratory viral detection in exacerbated versus
stable COPD).
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exacerbations of COPD and when stable for metapneumovi-
rus but all patients were negative.10 Rohde et al. found
metapneumovirus to be present in 2.3% of patients during
acute exacerbations of COPD and none of the stable COPD
patients in keeping with the findings of this study.18 The
detection of human metapneumovirus in this study confirms
its role as a respiratory pathogen in adult patients with
COPD.
The study showed relatively lower detection rates of
influenza virus compared to other studies.8e10 This may be
related to improved vaccination amongst this group of at
risk individuals and it may also reflect that during recruit-
ment for this study there was no influenza epidemic. There
was also a lower incidence of RSV infection (3 cases).Table 6 Respiratory viral infection and COPD stage
GOLD Stage Respiratory virus screen status
Respiratory virus
positive (%)
Respiratory virus negative
1 0 (0) 1
2 11 (31) 24
3 16 (31) 35
4 23 (47)a 26
a Chi squared test, comparison of groups 1e3 with group 4,
linear-by-linear association p < 0.05.Previous investigators have suggested that it is more
common. Some have suggested that it is present in low
copy numbers. It is possible that a more sensitive real-
time PCR assay is required in order to detect it.8 However
a recent study suggests that RSV accounted for 11.4% of
COPD admissions in hospitalised patients.19
This is the first study to also include a group of patients
from the same community who do not have respiratory
disease (non-obstructed smokers). There were similar
detection rates of respiratory viruses in the stable COPD
(11.8%) and NOS groups (12.5%) supporting previous findings
which found respiratory viral infection to be present in
asymptomatic individuals.6 The frequency of detection in
these groups suggests that COPD patients do not have
a higher carriage rate of viral infections to NOS but a larger
study is required in order to confirm this.
One of the weaknesses of this study was that patients
were recruited following admission to hospital. In some
cases there may be several days between infection,
development of symptoms and presentation. Depending
on the duration of viral infection prior to seeking medical
help there may be some cases in which patients present
late and thus viral replication is decreasing, resulting in
a reduced detection rate. This may lead to an underesti-
mation of the prevalence of viral infection in these
patients. Recent publications also suggest that RSV
detection is increased with the use of real-time PCR
assays.8 All respiratory viral assays in this study utilized
nested PCR technology and not real-time PCR methods.
Detection of respiratory viruses by PCR may in fact relate
to airway colonization20 or viral persistence.21 However,
several of the patients were seen at different time points
during this study and the same virus was not detected by
repeat sampling suggesting that those testing positive using
the PCR screen were experiencing an acute viral infection.
Another possible confounding factor is that patients
with COPD experience exacerbations in which no pre-
cipitating agent can be identified. These episodes may be
related to the progressive nature of this disease process
rather than an acute event. Thus the true role of re-
spiratory viral infection in exacerbations may be under-
estimated. A possible area of bias was that all patients
recruited were hospitalized. Thus selection bias may have
been imposed in that those patients admitted to hospital
tended to have particular types of respiratory viral in-
fection or that respiratory viral infection only precipitated
an exacerbation and subsequent hospital admission in
patients with severe COPD. Another potential source of
bias is the seasonality of respiratory viral infection. We
addressed this issue by recruiting patients during all
months of the year over a 2-year period. Other potential
sources of bias include patient selection; those patients
most ill and requiring non-invasive ventilation were too ill
to participate in the study.
Thompson et al. have published data linking influenza
and RSV infection with increased mortality in the elderly.22
There are increased admissions in older people in winter.
Fleming showed that acute respiratory infections are asso-
ciated with hospitalisation and increased mortality.23 It re-
inforces the health service implications of winter infection
and increased exacerbations of COPD. It is also noteworthy
that the peak death rate is in patients diagnosed with acute
1580 T.E. McManus et al.respiratory disease.23 Influenza has been linked with
increased health care use by the elderly and there is an
excess mortality particularly in the elderly.24 This paper
highlights the impact of respiratory viral infection on health
care resources. It supports the use of influenza vaccination
in patients with underlying respiratory disease in order to
reduce exacerbations and hospital admissions.
In conclusion this study supports the hypothesis that
respiratory viral infection is associated with exacerbations
of COPD. Rhinovirus was the most common infecting agent
identified and in two cases human metapneumovirus was
also detected. Dual infections were only seen amongst
those patients admitted to hospital with acute exacerba-
tions of COPD. The development of multiplexed real-time
PCR assays will enable this technology to be utilized in an
acute diagnostic setting.Acknowledgements
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